Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06740162 · ClinicalTrials.gov registry record · NA
Physical Activity and Community EmPOWERment Project
A NA study of Autism Spectrum Disorder and Down Syndrome, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- NA
- Development phase
- 376
- Enrollment target
- 2
- Study locations
NCT06740162: Recruiting NA study of Autism Spectrum Disorder and Down Syndrome, sponsored by University of North Carolina, Chapel Hill.
NCT06740162 is a NA study of Autism Spectrum Disorder and Down Syndrome that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 376 participants, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (181% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06740162, a NA study of Autism Spectrum Disorder and Down Syndrome, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- NA
- Development phase
- 376 participants
- Enrollment target
- 2
- Study locations
Study Summary
Purpose: Conduct a wait-list randomized controlled trial (RCT) of an inclusive physical activity program called PACE for adults with intellectual disability (ID) who are not yet showing signs of Alzheimer's Disease (AD)/age-related dementias (ARD). Participants: Participants include 120 adults with ID, their caregivers, and their coaches (up to 360 individual participants, grouped as triads), recruited through the University of North Carolina at Chapel Hill and the University of Arkansas. Participants also include 16 exercise professionals. Procedures (methods): Each cohort will include 20 triads who are randomly assigned to the PACE program or the waitlist control group.
Primary Outcome
The Actigraph GT9X Links measures daily step counts. Step counts less than 2500 are classified as basal, step counts between 2500 to 4999 are classified as limited, step counts between 5000 to 7499 are classified as low, step counts between 7500-9999 are classified as somewhat active, step counts between 10000 to 12499 are classified as active, and step counts over 12500 are classified as very active.
Conditions Studied
Interventions
- BEHAVIORAL PACE Program
Study Locations (2)
Arkansas
- University of Arkansas - Fayetteville
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2025-01-10 |
| Est. Completion | 2028-06 |
| Phase | NA |
What NCT06740162 shows while recruiting
NCT06740162 is an interventional study that assigns participants to a tested intervention. The registered 376 participants enrollment target is mid-sized for trials with a published cap, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (181% higher).
The record links to 10 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which PACE Program is the first listed.
NCT06740162 reports a single indexed study location in Arkansas, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06740162 about?
NCT06740162 is a clinical study titled "Physical Activity and Community EmPOWERment Project". Purpose: Conduct a wait-list randomized controlled trial (RCT) of an inclusive physical activity program called PACE for adults with intellectual disability (ID) who are not yet showing signs of Alzheimer's Disease (AD)/age-related dementias (ARD). Participants: Participants include 120 adults with...
What is the current status of trial NCT06740162?
This trial is currently recruiting. It is a NA study. The enrollment target is 376 participants. The study started on 2025-01-10. Estimated completion is 2028-06.
What conditions does trial NCT06740162 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Down Syndrome, Neurodevelopmental Disorders, Intellectual Disability, Fragile X Syndrome.
What interventions are being tested in trial NCT06740162?
The interventions under investigation include: PACE Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT06740162?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06740162 being conducted?
This trial has 2 study locations across Arkansas, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06740162's enrollment target sits among peer trials
376 18th of 224 higher than 207 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Online Pivotal Response Treatment Training in Autism Spectrum Disorder
RECRUITING · NA
-
Cerebellum and Autism: Regional Specialization for Social and Executive Functions
RECRUITING · NA
-
Milieu Teaching-AV (MT-AV Pilot)
RECRUITING · NA
-
STEPS Implementation Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
- NCT05055297 · 376 participants · NA
SELUTION4BTK Trial
- NCT05912647 · 376 participants · NA
Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes
- NCT05963971 · 376 participants · NA
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI